Evaluating the effect of galantamine HBr using Goal Attainment Scaling in a placebo controlled trial of mild to moderate Alzheimer's disease subjects

Trial Profile

Evaluating the effect of galantamine HBr using Goal Attainment Scaling in a placebo controlled trial of mild to moderate Alzheimer's disease subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2010

At a glance

  • Drugs Galantamine (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms VISTA
  • Most Recent Events

    • 03 Mar 2009 Status changed from not stated to completed as reported by ISRCTN: Current Controlled Trials.
    • 03 Mar 2009 Actual end date (9 Mar 2005) added as reported by ISRCTN: Current Controlled Trials.
    • 03 Mar 2009 Actual initiation date changed from 1 Jul 2001 to 29 Oct 2001 as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top